Jorge I. Vélez

Dr. Jorge I. Vélez

Universidad del Norte, Barranquilla, Atlántico, Colombia
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2010 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
MAMauricio Arcos-Burgos
Mauricio Arcos-Burgos
MJM Jain
M Jain
MAM T Acosta
M T Acosta
SSS Shively
S Shively
HSH Stanescu
H Stanescu
MMM Muenke
M Muenke
Attention-Deficit/Hyperactivity Disorder (ADHD) has a very high heritability (0.8), suggesting that about 80% of phenotypic variance is due to genetic factors. We used the integration of statistical and functional approaches to discover a novel gene that contributes to ADHD. For our statistical approach, we started with a linkage study based on large multigenerational families in a population isolate, followed by fine mapping of targeted regions using a family-based design. Family- and population-based association studies in five samples from disparate regions of the world were used for replication. Brain imaging studies were performed to evaluate gene function. The linkage study discovered a genome region harbored in the Latrophilin 3 gene (LPHN3). In the world-wide samples (total n=6360, with 2627 ADHD cases and 2531 controls) statistical association of LPHN3 and ADHD was confirmed. Functional studies revealed that LPHN3 variants are expressed in key brain regions related to attention and activity, affect metabolism in neural circuits implicated in ADHD, and are associated with response to stimulant medication. Linkage and replicated association of ADHD with a novel non-candidate gene (LPHN3) provide new insights into the genetics, neurobiology, and treatment of ADHD.

21 December 2009 in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
Verified
Journal Article
Closed access
PDF file
NYNicole M. Yanjanin
Nicole M. Yanjanin
Jorge I. VélezJorge I. Vélez
Jorge I. Vélez
AGAndrea Gropman
Andrea Gropman
KKKelly King
Kelly King
SBSimona E. Bianconi
Simona E. Bianconi
FPForbes Porter
Forbes Porter

1 July 2008 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
ERErich Roessler
Erich Roessler
MOMaia V. Ouspenskaia
Maia V. Ouspenskaia
JKJayaprakash D. Karkera
Jayaprakash D. Karkera
Jorge I. VélezJorge I. Vélez
Jorge I. Vélez
AKAmy Kantipong
Amy Kantipong
MMMaximilian Muenke
Maximilian Muenke

20 August 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
MMMaria Isabel Mosquera-Heredia
Maria Isabel Mosquera-Heredia
LBLuis Carlos Morales Burbano
Luis Carlos Morales Burbano
OVOscar Vidal
Oscar Vidal
EBernesto barceló
ernesto barceló
CSCarlos Silvera-Redondo
Carlos Silvera-Redondo
PGPilar Garavito-Galofre
Pilar Garavito-Galofre
Exosomes are extracellular vesicles released by cells, both constitutively and after cell activation, and are present in different types of biological fluid. Exosomes are involved in the pathogenesis of diseases, such as cancer, neurodegenerative diseases, pregnancy disorders and cardiovascular diseases, and have emerged as potential non-invasive biomarkers for the detection, prognosis and therapeutics of a myriad of diseases. In this review, we describe recent advances related to the regulatory mechanisms of exosome biogenesis, release and molecular composition, as well as their role in health and disease, and their potential use as disease biomarkers and therapeutic targets. In addition, the advantages and disadvantages of their main isolation methods, characterization and cargo analysis, as well as the experimental methods used for exosome-mediated drug delivery, are discussed. Finally, we present potential perspectives for the use of exosomes in future clinical practice.

26 January 2010 in American Journal of Medical Genetics Part C: Seminars in Medical Genetics
Verified
Journal Article
Closed access
PDF file
BSBenjamin D. Solomon
Benjamin D. Solomon
SMSandra Mercier
Sandra Mercier
Jorge I. VélezJorge I. Vélez
Jorge I. Vélez
DPDaniel E. Pineda‐Alvarez
Daniel E. Pineda‐Alvarez
AWAdrian Wyllie
Adrian Wyllie
MMMaximilian Muenke
Maximilian Muenke

16 November 2012 in Developmental Medicine & Child Neurology
Verified
Journal Article
Open access
PDF file
KWKarin S Walsh
Karin S Walsh
Jorge I. VélezJorge I. Vélez
Jorge I. Vélez
PKPeter G Kardel
Peter G Kardel
DIDaniel M Imas
Daniel M Imas
MMMaximilian Muenke
Maximilian Muenke
MAMaria T Acosta
Maria T Acosta
Aim  Difficulties in neurocognition and social interaction are the most prominent causes of morbidity and long‐term disability in children with neurofibromatosis type 1 (NF1). Symptoms of attention‐deficit–hyperactivity disorder (ADHD) have also been extensively recognized in NF1. However, systematic evaluation of symptoms of autism spectrum disorder (ASD) in children with NF1 has been limited.Method  We present a retrospective, cross‐sectional study of the prevalence of symptoms of ASD and ADHD and their relationship in a consecutive series of 66 patients from our NF1 clinic. The Social Responsiveness Scale and the Vanderbilt ADHD Diagnostic Parent Rating Scale were used to assess symptoms of ASD and ADHD.Results  Sixty‐six participants (42 males, 24 females) were included in this study. Mean age at assessment was 10 years 11 months (SD 5y 4mo). Forty percent of our NF1 sample had raised symptom levels reaching clinical significance on the Social Responsiveness Scale (T ≥ 60), and 14% reached levels consistent with those seen in children with ASDs (T ≥ 75). These raised levels were not explained by NF1 disease severity or externalizing/internalizing behavioral disorders. There was a statistically significant relationship between symptoms of ADHD and ASD (χ2=9.11, df=1, p=0.003, φ=0.56). Particularly salient were the relationships between attention and hyperactivity deficits, with impairments in social awareness and social motivation.Interpretation  We found that symptoms of ASD in our NF1 population were raised, consistent with previous reports. Further characterization of the specific ASD symptoms and their impact on daily function is fundamental to the development and implementation of effective interventions in this population, which will probably include a combination of medical and behavioral approaches.